Controversial FDA official Dr. Vinay Prasad departs agency

STAT

Vinay Prasad, a powerful FDA official, departs after controversy over rare disease drug

The Daily Beast

Top FDA Official Leaves Job After Laura Loomers Attacks

Reuters

Us Fdas Top Vaccine Official Vinay Prasad Leaves Agency After 3 Months 2025 07 30

Daily Wire

FDA Shake-Up: The Controversial Ouster Of The Top Vaccine Regulator

Newsweek

Top FDA Official Appointed By Trump Admin Departs After Three Months

RickSantorum

Fox 4 - Kansas City

Ap Fda Vaccine Chief Leaving Agency After Less Than 3 Months

FOX News

Trump Fda Overhauls Covid 19 Vaccine Approval Focus Older Populations High Risk Individual

Donald Trump

Trump 2024 Election Promises

Dr. Vinay Prasad resigned from his position as director of the FDA's Center for Biologics Evaluation and Research on Tuesday after serving only three months since his May appointment by Commissioner Marty Makary.</span

Bloomberg.com

Dr. Vinay Prasad resigned from his position as director of the FDA's Center for Biologics Evaluation and Research on Tuesday after serving only three months since his May appointment by Commissioner Marty Makary.

Prasad and FDA Commissioner Makary asked Sarepta Therapeutics to halt shipments of gene therapy Elevidys this month following three deaths linked to the company's treatments, though the agency later reversed course.</span

Prasad and FDA Commissioner Makary asked Sarepta Therapeutics to halt shipments of gene therapy Elevidys this month following three deaths linked to the company's treatments, though the agency later reversed course.

Right-wing activist Laura Loomer publicly criticized Prasad as a "progressive leftist saboteur," highlighting his past social media posts supporting Bernie Sanders and expressing criticism of Trump.</span

Right-wing activist Laura Loomer publicly criticized Prasad as a "progressive leftist saboteur," highlighting his past social media posts supporting Bernie Sanders and expressing criticism of Trump.

During his tenure, Prasad overruled FDA scientists' recommendations for broad COVID-19 vaccine approval, limiting use to seniors and high-risk individuals rather than the general population.</span

The Associated Press

During his tenure, Prasad overruled FDA scientists' recommendations for broad COVID-19 vaccine approval, limiting use to seniors and high-risk individuals rather than the general population.

The Department of Health and Human Services stated Prasad "did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California".</span

The Department of Health and Human Services stated Prasad "did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California".

George Tidmarsh, recently appointed to lead the FDA's Center for Drug Evaluation and Research, will serve as acting director of Prasad's former division while a permanent replacement is sought.</span

George Tidmarsh, recently appointed to lead the FDA's Center for Drug Evaluation and Research, will serve as acting director of Prasad's former division while a permanent replacement is sought.

CNN #3395

STAT #

The Daily Beast #

Reuters #

Daily Wire #

Newsweek #2944

Fox 4 - Kansas City #

FOX News #

The Associated Press #

Prasad's resignation shows how pharmaceutical lobbying and political pressure can undermine legitimate safety concerns at the FDA. His evidence-based approach to drug approvals and willingness to question treatments with questionable efficacy represented exactly the kind of scientific rigor the agency needs. The coordinated attack against him prioritized industry profits over patient safety.

Prasad's resignation shows how pharmaceutical lobbying and political pressure can undermine legitimate safety concerns at the FDA. His evidence-based approach to drug approvals and willingness to question treatments with questionable efficacy represented exactly the kind of scientific rigor the agency needs. The coordinated attack against him prioritized industry profits over patient safety.

FDA's Top Vaccine Official Vinay Prasad Resigns After 3 Months

Medicine & healthcare

United States of America

Vaccination

Prasad's departure represents a victory against regulatory overreach that threatened patient access to life-saving treatments. His decision to halt Elevidys shipments ignored desperate families fighting Duchenne muscular dystrophy and demonstrated dangerous government interference in medical decisions. The Wall Street Journal correctly identified this as regulatory "mugging" that chills pharmaceutical innovation.

Prasad's departure represents a victory against regulatory overreach that threatened patient access to life-saving treatments. His decision to halt Elevidys shipments ignored desperate families fighting Duchenne muscular dystrophy and demonstrated dangerous government interference in medical decisions. The Wall Street Journal correctly identified this as regulatory "mugging" that chills pharmaceutical innovation.

Fda Vinay Prasad Exits After Sarepta Gene Therapy Controversy

FDA's Top Vaccine Official Vinay Prasad Resigns After 3 Months

FDA's Top Vaccine Official Vinay Prasad Resigns After 3 Months

The Spin

The Controversies

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

FDA's Top Vaccine Official Vinay Prasad Resigns After 3 Months

FDA's Top Vaccine Official Vinay Prasad Resigns After 3 Months

The Spin

The Controversies

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters